Innoviva, Inc. (INVA) Stock Score, Valuation & Financial Research
Innoviva, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 81/100.
Quick answer for INVA
Innoviva, Inc. currently has a Wall Street Score of 81/100. The stored market price is $20.62. Its financial score is 49/100. Its valuation score is 100/100. The latest WSS change is +0.4 points. These figures are a research snapshot, not a buy or sell recommendation.
What Innoviva, Inc. does
Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in
INVA financial snapshot
- Wall Street Score:
- 81/100
- Current price:
- $20.62
- Market capitalization:
- $1.52B
- Revenue:
- $443.4M
- Net income:
- $357.2M
- Free cash flow:
- $186.4M
- Cash:
- $570.4M
- Total debt:
- $269.7M
- EPS:
- 4.02
- P/E ratio:
- 5.1x
- Financial score:
- 49/100
- Valuation score:
- 100/100
- Revenue score:
- 56/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $186.4M, showing positive cash generation.
- The balance sheet shows $570.4M of cash versus $269.7M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +0.4 points: INVA increased 0.4 points because Revenue improved by 4.5 points.
What the numbers mean
Its current valuation score is 100/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 49/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research INVA
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.